fda warning letters compounded semaglutide september 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA issued 25 warning letters

This was a randomized, head-to-head comparison that enrolled 751 individuals and found those who took tirzepatide lost 20% of their body weight, about 50 pounds on average, while those on semaglutide lost 14% of their body weight, or about 33 pounds on average

were struggling to stock some of the newest weight-loss medications

Wegovy is specifically approved for weight management in adults with obesity or those who are overweight with weight-related health conditions

The main renal dysfunctions are due to the thickening of the glomerular basement membranes, formed of microaneurysms and development of mesangial nodules